Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
18 evidence topics · 21 sources
Variable clinical course: growth, stabilization, and regression
“According to estimates, approximately 10–28% of DT will resolve spontaneously without treatment (22% for extra-abdominal tumors to 28% for abdominal tumors)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“30% will cycle through progression and resolution, 50% will remain stable after diagnosis, and 10% will progress rapidly” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance: pooled analysis of three prospective observational studies, extra-abdominal desmoid-type fibromatosis
“Three prospective observational studies (Italy, the Netherlands, and France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis support AS as a first-line approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients ( n = 282) with a median follow-up of 53 months (IQR, 39–63) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study confirms that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance: Italian prospective multicenter observational study, primary sporadic desmoid fibromatosis
“This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From 2013 to 2018, 108 consecutive patients were included (82% female); median age was 39 years; median size was 51 mm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance: prospective multicenter observational study of primary sporadic tumors of the extremity or abdominal or thoracic wall
“This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between 2012 and 2015, 100 patients were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance at all anatomic locations: United Kingdom sarcoma reference center
“Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Surgery compared with wait-and-see: prospective cohort of 771 cases
“We conducted a prospective study of 771 confirmed cases of DTF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Event-free survival in the ALTITUDES nationwide prospective cohort
“ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We enrolled 628 patients managed by active surveillance, surgical resection, or systemic treatment as first-line therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The first-line management was active surveillance in 352 (68.2%), surgical resection in 120 (23.3%), and systemic treatments in 44 (8.5%) patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median follow-up period was 24.7 (range, 0.4-59.7) months. The estimated 3-year EFS rate was 66.2% [95% confidence interval (CI), 60.5%-71.2%].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Spontaneous regression in the placebo group of a prospective trial
“Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Spontaneous regression is reported in up to 20% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our prospective trial, in which desmoid tumors in patients who were taking placebo were evaluated, provides evidence in support of an initial period of observation in patients with newly diagnosed desmoid tumors, given that 20% of the patients in the placebo group had disease regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Local recurrence after complete gross resection: nomogram cohort of 439 patients
“Of 439 patients undergoing complete gross resection, 100 (23%) had recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year local recurrence–free survival (LRFS) was 69%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Abdominal wall tumors had the best outcome (5-year LRFS 91%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Local recurrence after surgery: participant-reported data
Recurrence by tumor location and familial adenomatous polyposis status
“Tumors on extremities are believed to be locally aggressive and have recurrence rates ranging from 24% to 77%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Local recurrence rates of intra-abdominal tumors in patients with FAP are higher than those for extra-abdominal tumors and reported to be 57–86%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: desmoid tumors overall
“While lacking metastatic potential, the natural history of DT is variable and ranges from an asymptomatic, indolent course to aggressive infiltration of neurovascular structures and vital organs resulting in pain, disfigurement, organ dysfunction, and— rarely—death (usually related to complications such as intestinal obstruction associated with progression of intra-abdominal tumors)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality after resection: nomogram cohort
“Eight patients died of disease, all after R2 resection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 44 patients were dead at last follow-up, but only 8 died of disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients died following intestinal transplant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Danish patients compared with a healthy matched cohort
“that has reported a 5-year mortality rate of 7 per 1000 [95% confidence interval (CI) 3–16] among Danish patients with DT as compared with 5 per 1000 (95% CI, 4–7) in a healthy matched cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The authors state that most deaths occurred in patients with FAP, though they represented only 7% of patients in the DT cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: intra-abdominal desmoid tumors in familial adenomatous polyposis by stage
“Intra-abdominal desmoid tumors are one of the leading causes of death in patients with familial adenomatous polyposis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 154 patients with intra-abdominal desmoid tumors were included in the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year survival of patients with stage I, II, III, and IV intra-abdominal desmoid tumor were 95%, 100%, 89%, and 76% respectively (P < 0.001). Severe pain/narcotic dependency, tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define survival within stages. Five-year survival rate of stage IV patient with all of the above-mentioned risk factors was only 53%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: home parenteral nutrition in familial adenomatous polyposis-associated intra-abdominal desmoids
“Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The need for HPN represented a strong predictor of mortality (5-year survival HPN = 72% vs non-HPN = 95%), but duration of HPN did not affect mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid disease as a cause of death in familial adenomatous polyposis
“Desmoid is a major source of mortality in FAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Desmoid tumours (DT) are one of the main causes of death in patients with familial adenomatous polyposis (FAP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Desmoid tumors (DT) are a leading cause of morbidity and mortality in patients with familial adenomatous polyposis (FAP), yet available data on DT risk remain limited and have been largely derived from large registries or tertiary referral centers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote